Drugs / SHR-1905
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04800263 | Jul 2021 → Nov 2022 | asthma | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04905602 | Jun 2021 → Oct 2023 | asthma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07211542 | Nov 2025 → Sep 2026 overdue | atopic eczema | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06786455 | Jan → Dec 2025 | asthma | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05891483 | Sep 2023 → Feb 2026 | chronic rhinosinusitis | Guangdong Hengrui Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT05593250 | Jan 2023 → Dec 2026 expected | asthma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07098403 | Sep 2025 → Jan 2028 expected | asthma | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07132827 | Aug 2025 → Apr 2028 expected | chronic rhinosinusitis | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1905 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04800263 ↗ |
| Action | Inhibit | “inhibits TSLP bioactivity” PMID 39076593 ↗ Jul 2024 |
| Modality | Monoclonal antibody | “SHR-1905 is a humanized immunoglobulin G1 kappa monoclonal antibody” PMID 39076593 ↗ Jul 2024 |
| Route | Subcutaneous | “subcutaneous SHR-1905” PMID 39076593 ↗ Jul 2024 |